Last reviewed · How we verify
Lidocaine + Prilocaine
Lidocaine and prilocaine are local anesthetics that block sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.
Lidocaine and prilocaine are local anesthetics that block sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses. Used for Topical anesthesia of intact skin prior to minor surgical procedures, Anesthesia for venipuncture and intravenous cannulation, Relief of pain associated with minor skin procedures.
At a glance
| Generic name | Lidocaine + Prilocaine |
|---|---|
| Also known as | Nanorap® |
| Sponsor | Galeno Desenvolvimento de Pesquisas Clínicas |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia/Pain Management |
| Phase | FDA-approved |
Mechanism of action
Both agents are amide-type local anesthetics that work by inhibiting sodium influx through voltage-gated sodium channels in neuronal membranes, thereby stabilizing the membrane and preventing depolarization. This combination is commonly formulated as EMLA cream (Eutectic Mixture of Local Anesthetics), where the two drugs form a eutectic mixture with enhanced penetration through intact skin. The synergistic effect allows for effective topical anesthesia with reduced systemic toxicity compared to either agent alone.
Approved indications
- Topical anesthesia of intact skin prior to minor surgical procedures
- Topical anesthesia for venipuncture and intravenous cannulation
- Topical anesthesia for dermatological procedures
Common side effects
- Skin blanching or erythema at application site
- Temporary skin pallor
- Methemoglobinemia (rare, especially in infants)
- Local irritation or allergic contact dermatitis
Key clinical trials
- Efficacy and Safety of Combined Nanofat Injection With Either Platelet Rich Fibrin or Microneedling Versus Nanofat Injection Alone in the Treatment of Facial Atrophic Post Acne Scars (NA)
- Virtual Reality for Port-a-Cath Access (NA)
- EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers (PHASE2)
- Virtual Reality Goggle Utilization for Venipuncture Distraction (NA)
- Comparative Study of Two Topical Anesthetics Prior to Fractional Nonablative Laser Treatment of the Face (PHASE2, PHASE3)
- The Effect of Interventional Procedures on Serum CGRP and PACAP-38 Levels in Chronic Migraine (NA)
- Oral Hyoscine vs. Topical EMLA vs. Placebo for Pain Reduction During Hysterosalpingography (NA)
- Diminishing Accelerated Long-term Forgetting in Mild Cognitive Impairment (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lidocaine + Prilocaine CI brief — competitive landscape report
- Lidocaine + Prilocaine updates RSS · CI watch RSS
- Galeno Desenvolvimento de Pesquisas Clínicas portfolio CI